Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma [0.03%]
自体多抗原特异性内源性T细胞(MASE-T)治疗转移性黑色素瘤的安全性和可行性研究
T J Monberg,S A Tvingsholm,M Svensson-Frej et al.
T J Monberg et al.
Background: Tumor-infiltrating lymphocyte (TIL) therapy is effective in metastatic melanoma (MM), but the need for resectable tumor tissue limits its accessibility. Antigen-presenting scaffolds (Ag-scaffolds) constitute a...
Adjuvant anti-PD-1 therapy in high-risk cutaneous squamous-cell carcinoma: post hoc insights from the C-POST and KEYNOTE-630 studies [0.03%]
高危皮肤鳞状细胞癌辅助抗PD-1治疗的回顾性分析：C-POST和KEYNOTE-630研究的新发现
S Cavalieri,A Ottini,C Bergamini et al.
S Cavalieri et al.
Background: Cutaneous squamous-cell carcinoma (cSCC) is cured with surgery with or without radiotherapy in most cases, but patients with high-risk features remain prone to recurrence. Until recently, no systemic adjuvant ...
Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial) [0.03%]
评估Selicrelumab联合Atezolizumab治疗复发或难治B细胞淋巴瘤患者的安全性和疗效的Ⅰb期临床试验（ITSELF研究）
N Alshatti,F Lemonnier,E Bachy et al.
N Alshatti et al.
Background: The efficacy of immune checkpoint blockade therapy requires pre-existing antitumor immunity. Defective antigen presentation during the priming phase can reduce the generation of tumor-specific T cells, which a...
Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care [0.03%]
refractory 微卫星稳定型转移性结直肠癌：Botensilimab+Balstilimab与当前标准治疗的比较
E Bengala,D Santini,V Picone
E Bengala
Background: The combination of botensilimab + balstilimab demonstrated promising clinical activity in heavily pre-treated patients with microsatellite-stable metastatic colorectal cancer (mCRC) in a recently published pha...
Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells [0.03%]
V区Ig含T细胞活化抑制分子和程序性死亡-1配体的相互作用可抑制T细胞的抗癌活性
M Abooali,X Lei,I M Yasinska et al.
M Abooali et al.
Background: V-domain immunoglobulin-containing suppressor of T cell activation (VISTA) is a unique multifunctional immune checkpoint protein, which can display both receptor and ligand properties. It plays a crucial role ...
Phase II trial on nivolumab plus hypofractionated radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial [0.03%]
一项关于尼伏单抗联合减分数放疗治疗黏膜黑色素瘤患者的II期研究——PORTER-M3试验
M Nomura,M Yoshimura,T Yokota et al.
M Nomura et al.
Background: The response rate of nivolumab monotherapy for mucosal melanoma is only ∼20%. The objective of this phase II trial was to evaluate the efficacy and safety of nivolumab in combination with radiotherapy for met...
Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab [0.03%]
用于转移性脉络膜黑色素瘤患者的孤立肝灌注联合伊匹木单抗和纳武利尤单抗治疗的纵向ctDNA监测
M Kadefors,A Nelson,E Blomberg et al.
M Kadefors et al.
Background: Uveal melanoma (UM) is a rare cancer, which often metastasizes to the liver, leading to a poor prognosis. In the randomized SCANDIUM II trial, patients with metastatic UM received a one-time treatment with iso...
Intratumoral microbiome is associated with the response to cancer immunotherapy in lung cancer patients with high PD-L1 expression [0.03%]
高PD-L1表达非小细胞肺癌患者中肿瘤内菌群与免疫治疗疗效相关性研究
F Shoji,T Kawabata,K Kosai et al.
F Shoji et al.
Background: High expression of tumoral programmed death-ligand 1 (PD-L1) [high PD-L1 tumor proportion score (TPS)] is a predictive biomarker of response to cancer immunotherapy in lung cancer; however, its predictiveness ...
Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients [0.03%]
转移病灶影响四期黑色素瘤患者的疾病进展模式和生存期
I A Vergara,S N Lo,I Li et al.
I A Vergara et al.
Background: Metastatic sites influence response rates to immune checkpoint inhibitors (ICI) and survival, suggesting anatomical locations impact treatment outcomes. This study examines how baseline metastatic sites affect...
Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy [0.03%]
TCR谱型的利用：肿瘤免疫治疗中的预测性和治疗监测能力
J Chiffelle,R Genolet,O Michielin et al.
J Chiffelle et al.
The T-cell receptor (TCR) repertoire, representing the vast diversity of T cells, is a cornerstone of adaptive immunity and a powerful tool in oncology. Advances in high-throughput sequencing have enabled deep profiling of TCR diversity and...